Why High Risk Does Not Automatically Make a Strong Screening Case
This series examines medical care for adults with Down syndrome through a focused question: when a condition is more common, or appears biologically plausible, what evidence is still needed before routine screening can be expected to help? The practical judgment is not whether adults with Down syndrome deserve more medical attention—they do—but how that attention should connect risk, testing, diagnosis, treatment, meaningful outcomes, and possible harm. By the end of this opening, the reader should be able to distinguish a reason to look carefully from proof that a screening program produces more benefit than burden.
The adult Down syndrome care problem is not one risk profile
Down syndrome is a genetic condition involving an extra full or partial copy of chromosome 21. Its medical significance is not captured by a single risk score. The 2020 Global Down Syndrome Foundation guideline describes a disease spectrum that differs both from the general population and from people with other intellectual or developmental disabilities. Some conditions occur more often; others occur less often; and the pattern changes over the life course.
That combination matters because ordinary preventive care often begins with a population assumption. If a disease is common in the general population, clinicians may reasonably ask whether people in front of them should be screened. But the answer can change when the underlying population has a different distribution of disease. The 2026 AHRQ evidence review reports higher prevalence among adults with Down syndrome for conditions including Alzheimer’s disease, diabetes, hypothyroidism, leukemia, obesity, obstructive sleep apnea, cataracts, and several bone, joint, and mobility conditions. It also reports lower prevalence for several solid tumors and for some cardiovascular conditions, including coronary atherosclerosis and hypertension. “Higher risk” is therefore not a universal property of every condition, and “lower risk” does not mean that all cardiovascular or cancer-related concerns disappear.
The adult context makes the issue more urgent. Life expectancy has risen dramatically, while adult services and preventive systems have not always kept pace. The AHRQ report notes that nearly 40 percent of adults with Down syndrome aged 26 and older still receive primary care from pediatric providers, and that fewer than half receive annual well examinations. It also describes diagnostic overshadowing: the tendency to attribute a new health concern to Down syndrome itself rather than investigate another medical condition. Communication or learning differences can further obscure symptoms. A change in daily functioning may be interpreted as a baseline trait; a sensory problem may be mistaken for a cognitive limitation; a physical illness may be treated as a psychiatric problem.
These barriers create a genuine danger of under-recognition. A person may need more attentive history-taking, better continuity, and a clinician who knows how their baseline function looks. The guideline’s emphasis on caregivers, family members, and the adult’s own observations responds to that reality. But the existence of under-recognition does not settle every testing question. A test can find an abnormality without identifying who will benefit from treatment. It can also produce false positives, additional procedures, anxiety, medication exposure, or restrictions on activities that support physical and psychological health. The challenge is to improve recognition without confusing more measurement with better care.
What must happen after a screening test?
The word “screening” can conceal several different claims. A prevalence study asks how often a condition is found. A diagnostic-validity study asks whether a tool distinguishes people with and without a condition under specified circumstances. A treatment study asks whether an intervention changes an outcome after a condition has been identified. A screening-effectiveness study asks something larger: whether offering the test to a defined population, compared with another strategy or no screening, leads to better outcomes after all the downstream steps are included.
Those steps matter. An elevated result may lead to a diagnosis, but the diagnosis may be uncertain. A diagnosis may lead to treatment, but the treatment may not improve function or quality of life in this population. A test may be accurate in a research setting but difficult to complete in routine care. A screening program may detect disease earlier while also creating overdiagnosis or unnecessary treatment. The relevant outcome is not simply the number of positive tests. It may be fewer complications, better daily functioning, improved quality of life, longer survival, or better support for the adult and their caregivers. Harms include more than physical adverse events: they can include medical trauma, loss of time, cost, access barriers, and the consequences of acting on an uncertain result.
The AHRQ review made this chain explicit. Its first key question asked about the benefits, harms, and considerations of screening and diagnostic interventions for co-occurring conditions in adults with Down syndrome. The review was looking for evidence of earlier detection, accurate diagnosis, time to treatment, health and quality-of-life outcomes, and harms related to screening or diagnosis. Its second key question concerned treatment. Separate contextual questions addressed prevalence and the presentation of behavioral or mental-health conditions. Keeping these questions separate prevents a common logical jump: using evidence that a condition is common as if it were evidence that screening for it improves outcomes.
The distinction is not merely academic. After screening 8,680 unique references, the AHRQ review identified 36 eligible treatment studies and no eligible studies that directly evaluated the benefits or harms of screening or diagnostic interventions. Its prevalence search found a larger body of contextual material, but that material could not fill the missing link. The finding means that the review could not estimate the comparative net benefit of screening within its adult-specific criteria. It does not mean that screening has no value, that tests never help a symptomatic person, or that clinicians should ignore a treatable condition.
It also explains why the report uses the word “insufficient” carefully. AHRQ evaluates evidence through study limitations, consistency, directness, precision, and reporting bias. An insufficient rating means that the evidence cannot support a meaningful judgment about the effect at that time. It is not a synonym for ineffective. A small study may suggest benefit, but if it is unreplicated, imprecise, or vulnerable to bias, the responsible conclusion remains that the size and reliability of the benefit are uncertain.
The cases that make the distinction visible
The contrast becomes clearer when the same population is viewed through different conditions. Dementia is a case where risk is high, age matters, and longitudinal observation may be more informative than a single label. Alzheimer’s disease is substantially more common in adults with Down syndrome, and clinical dementia is uncommon before 40 but rises sharply in later decades. The GLOBAL guideline consequently recommends annual assessment from age 40 for changes from baseline, including input from primary caregivers and attention to cognition, behavior, communication, adaptive function, motor skills, and established abilities. Yet it also cautions against assuming that every decline is Alzheimer-type dementia. Hypothyroidism, sleep apnea, seizures, sensory impairment, medication effects, and psychiatric or metabolic conditions can alter function. Here, careful surveillance and differential diagnosis are connected; high prevalence does not justify skipping the question of cause.
Thyroid disease and diabetes illustrate a different judgment. The 2020 guideline recommends periodic laboratory screening because hypothyroidism is common, symptoms such as fatigue, weight gain, and constipation are difficult to interpret, and diabetes can cause treatable long-term complications. Those recommendations are classified as weak for. The guideline also states that no studies had shown that screening asymptomatic adults with Down syndrome improves clinical outcomes. The recommendation is therefore a reasoned balance of prevalence, treatability, burden, and values—not a direct estimate from a screening trial. That distinction does not make the recommendation meaningless. It tells the reader how much confidence to attach to its interval and why individual circumstances still matter.
The reverse pattern appears with atlantoaxial instability and osteoporosis. An abnormal cervical X-ray can identify radiographic instability, but the guideline found no evidence that routine X-rays in asymptomatic adults reduce spinal cord injury or that the radiographic finding predicts progression to injury. It recommends against routine asymptomatic X-ray screening and favors attention to symptoms and signs of myelopathy. Adults with Down syndrome may also have low bone mineral density, but general fracture-risk models were derived from people without Down syndrome, and the clinical meaning of a low measurement is not fully calibrated for this population. The guideline therefore supports shared decision-making rather than automatically applying established osteoporosis screening rules.
These examples are not contradictions. They ask different questions about prediction, action, and consequence. Sleep apnea may be common and important to treat, yet its prevalence estimates vary sharply depending on whether researchers use administrative records, questionnaires, or sleep studies. Cardiovascular risk may be lower for atherosclerotic disease while remaining important through congenital heart disease and cardioembolic stroke. Obesity may justify annual monitoring and prevention even though small intervention studies have not shown a reliable reduction in medical complications. The relevant question is always more specific than “Is this condition high risk?” It is: “For this condition, in this population, with this test and this follow-up pathway, what happens to the adult if we screen—and what happens if we do not?”
That question carries the series forward. The next step is to examine what an eligible study would have to compare and measure before a screening practice could be said to improve the lives of adults with Down syndrome, rather than merely increase the number of conditions detected.